Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › MenACWY CRM

MenACWY CRM

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of MenACWY CRM

16 trials tracked of MenACWY CRM: 13 in phase 3 or 4 and 1 with published results. The most-cited published study has 17 citations.

16Trials tracked
13Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 12 Phase 2 3
  1. Phase 3 A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. Completed · 17 cited
  2. Phase 4 Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea Completed
  3. Phase 3 MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age Completed
  4. Phase 3 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults Completed
  5. Phase 3 Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers Completed
  6. Phase 3 Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. Completed
Show 10 more trials
  1. Phase 3 Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine Completed
  2. Phase 3 Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia Completed
  3. Phase 3 Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine Completed
  4. Phase 3 Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life Completed
  5. Phase 3 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults Completed
  6. Phase 3 Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children Completed
  7. Phase 3 A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months Completed
  8. Phase 2 B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants Completed
  9. Phase 2 Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months) Completed
  10. Phase 2 Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers Completed

Showing the 16 most-cited and recently-updated of 16 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.